Octapharma announced that wilate (double virus inactivated von Willebrand Factor/Coagulation Factor VIII concentrate [human]) is now available by prescription for the treatment of spontaneous or trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) as well as in patients with mild or moderate forms of the illness in whom the use of desmopressin is known or suspected to be ineffective or contraindicated.

Wilate is a coagulation factor complex first approved by the FDA in December 2009.

For more information call (201) 604-1130 or visit www.octapharma.com.